FY2026 Earnings Estimate for EYPT Issued By Chardan Capital

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) - Analysts at Chardan Capital issued their FY2026 EPS estimates for shares of EyePoint Pharmaceuticals in a research note issued on Monday, March 24th. Chardan Capital analyst D. Gataulin expects that the company will post earnings per share of ($2.82) for the year. Chardan Capital has a "Buy" rating and a $33.00 price objective on the stock. The consensus estimate for EyePoint Pharmaceuticals' current full-year earnings is ($2.13) per share.

EyePoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last issued its quarterly earnings results on Wednesday, March 5th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.54) by ($0.10). EyePoint Pharmaceuticals had a negative net margin of 226.57% and a negative return on equity of 43.01%. The business had revenue of $11.60 million during the quarter, compared to analyst estimates of $11.02 million.

EYPT has been the subject of several other research reports. Citigroup initiated coverage on EyePoint Pharmaceuticals in a report on Tuesday, January 7th. They set a "buy" rating and a $33.00 price objective for the company. StockNews.com upgraded shares of EyePoint Pharmaceuticals to a "sell" rating in a report on Friday, March 14th. Finally, HC Wainwright reiterated a "buy" rating and set a $22.00 price objective on shares of EyePoint Pharmaceuticals in a report on Thursday, March 6th. One investment analyst has rated the stock with a sell rating and nine have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $26.63.

Remove Ads

EyePoint Pharmaceuticals Stock Down 1.4 %

NASDAQ:EYPT traded down $0.08 during trading hours on Wednesday, reaching $5.83. The company had a trading volume of 370,170 shares, compared to its average volume of 891,213. The business's 50-day simple moving average is $6.79 and its two-hundred day simple moving average is $8.23. EyePoint Pharmaceuticals has a twelve month low of $5.54 and a twelve month high of $23.65. The firm has a market cap of $400.69 million, a price-to-earnings ratio of -2.92 and a beta of 1.41.

Institutional Investors Weigh In On EyePoint Pharmaceuticals

Several large investors have recently modified their holdings of EYPT. Geode Capital Management LLC raised its stake in shares of EyePoint Pharmaceuticals by 16.1% in the third quarter. Geode Capital Management LLC now owns 1,199,056 shares of the company's stock valued at $9,583,000 after buying an additional 166,699 shares during the period. Charles Schwab Investment Management Inc. increased its position in shares of EyePoint Pharmaceuticals by 5.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 142,763 shares of the company's stock valued at $1,141,000 after buying an additional 7,967 shares during the period. Barclays PLC grew its stake in EyePoint Pharmaceuticals by 410.4% during the third quarter. Barclays PLC now owns 245,045 shares of the company's stock valued at $1,959,000 after acquiring an additional 197,033 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in EyePoint Pharmaceuticals by 1,171.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 371,758 shares of the company's stock worth $2,970,000 after purchasing an additional 342,516 shares in the last quarter. Finally, Franklin Resources Inc. boosted its holdings in EyePoint Pharmaceuticals by 9.9% in the 3rd quarter. Franklin Resources Inc. now owns 4,012,048 shares of the company's stock valued at $32,056,000 after purchasing an additional 362,399 shares during the period. Hedge funds and other institutional investors own 99.41% of the company's stock.

EyePoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.